Company intelligence / Profile preview
Clanotech
Stockholm, Swedenclanotech.se ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Clanotech’s lead program, CLT-28643, is a small molecule antagonist of integrin α5β1 and has shown promising anti-angiogenic, anti-fibrotic and anti-inflammatory activity in animal models for glaucoma. Orphan drug designation has been granted in both US and EU for prevention of scarring post-glaucoma surgery. A phase I/II clinical trial was being prepared as of last update.
- Therapeutic areas
- OncologyOphthalmologyOther
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Clanotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clanotech.